[go: up one dir, main page]

AU3244693A - Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock - Google Patents

Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock

Info

Publication number
AU3244693A
AU3244693A AU32446/93A AU3244693A AU3244693A AU 3244693 A AU3244693 A AU 3244693A AU 32446/93 A AU32446/93 A AU 32446/93A AU 3244693 A AU3244693 A AU 3244693A AU 3244693 A AU3244693 A AU 3244693A
Authority
AU
Australia
Prior art keywords
combination
necrosis factor
tumor necrosis
septic shock
factor plus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32446/93A
Inventor
Beverly E Barton
James V Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU3244693A publication Critical patent/AU3244693A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU32446/93A 1991-12-17 1992-12-15 Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock Abandoned AU3244693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80969691A 1991-12-17 1991-12-17
US809696 1991-12-17

Publications (1)

Publication Number Publication Date
AU3244693A true AU3244693A (en) 1993-07-19

Family

ID=25202012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32446/93A Abandoned AU3244693A (en) 1991-12-17 1992-12-15 Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock

Country Status (2)

Country Link
AU (1) AU3244693A (en)
WO (1) WO1993011793A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69405102T2 (en) * 1993-06-03 1998-01-15 Therapeutic Antibodies, Inc., Nashville, Tenn. ANTIBODY FRAGMENTS IN THERAPY
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US5601814A (en) * 1994-08-05 1997-02-11 Schering Corporation Use of IL-6 to treat toxic shock
WO1996004012A1 (en) * 1994-08-05 1996-02-15 Schering Corporation Use of the combination of chlorpromazine plus interleukin-6 to treat or prevent septic shock
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
DE10054279A1 (en) * 2000-11-02 2002-05-16 Apotech Res & Dev Ltd Use of ligands from death receptors or RIP to trigger caspase-independent cell death and compounds to inhibit caspase-independent cell death
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI556829B (en) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 Multiple variable dose therapy for the treatment of TNFα-related disorders
MX2007014440A (en) 2005-05-16 2008-02-11 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis.
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of rheumatoid arthritis
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of psoriatic arthritis
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0374510B1 (en) * 1988-12-19 1997-01-15 American Cyanamid Company Products for the treatment of endotoxic shock in a mammal

Also Published As

Publication number Publication date
WO1993011793A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
AU3244693A (en) Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
AU2156092A (en) Use of polymerized hemoglobin to increase the antitumor effect of the ionizing radiation
AU4199489A (en) Composition for the treatment of erectile dysfunction
EP0749475A4 (en) Use of the cytokine ip-10 as an anti-tumor agent
AU3222093A (en) Progressive jackpot twenty-one
AU1441792A (en) Megakaryocyte stimulating factors
EG20016A (en) Use of acetals
AU3007492A (en) Treatment of wastewater
EP0497333A3 (en) Purification of aminonitriles or diamines
AU8170291A (en) Ground- and wastewater purification
HU9301509D0 (en) Tnf inhibitors
ZA928198B (en) Substituted azaspiranes for use in the treatment of hyperlipidemia
GB2253463B (en) Improvements relating to taps
AU2286092A (en) Adjustable bed
AU3202395A (en) Use of the combination of chlorpromazine plus interleukin-6 to treat or prevent septic shock
GB9100562D0 (en) Structure of ash-tray assembly
ZA923900B (en) 3-fused pyridiniummethyl cephalosporins
AU7323091A (en) Treatment of wastewater
HU9400358D0 (en) Use of quinoziline derivatives as orexigenics
PL271986A1 (en) Receiver of the lateral sonar with distributional adjustment of the amplification
ZA925329B (en) The manufacture of filter elements
PL52621Y1 (en) Lighter of the operative field
NZ241220A (en) Preparation of activated carbon
GB9125704D0 (en) New use of il-6
GB9226337D0 (en) Inhibition of cytokine production